Kim Mi-Hyun, Kim Soo Han, Lee Min Ki, Eom Jung Seop
Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Republic of Korea.
Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea.
Tuberc Respir Dis (Seoul). 2024 Jan;87(1):31-39. doi: 10.4046/trd.2023.0085. Epub 2023 Nov 15.
After the successful development of targeted therapy and immunotherapy for the treatment of advanced-stage non-small cell lung cancer (NSCLC), these innovative treatment options are rapidly being applied in the adjuvant setting for early-stage NSCLC. Some adjuvants that have recently been approved include osimertinib for epidermal growth factor receptor-mutated tumors and atezolizumab and pembrolizumab for selected patients with resectable NSCLC. Numerous studies on various targeted therapies and immunotherapy with or without chemotherapy are currently ongoing in the adjuvant setting. However, several questions regarding optimal strategies for adjuvant treatment remain unanswered. The present review summarizes the available literature, focusing on recent advances and ongoing trials with targeted therapy and immunotherapy in the adjuvant treatment of early-stage NSCLC.
在针对晚期非小细胞肺癌（NSCLC）的靶向治疗和免疫治疗取得成功发展之后，这些创新的治疗选择正在迅速应用于早期NSCLC的辅助治疗中。最近获批的一些辅助治疗药物包括用于表皮生长因子受体突变肿瘤的奥希替尼，以及用于部分可切除NSCLC患者的阿替利珠单抗和帕博利珠单抗。目前，在辅助治疗领域，针对各种靶向治疗和免疫治疗（联合或不联合化疗）的众多研究正在进行中。然而，关于辅助治疗的最佳策略仍有几个问题尚未得到解答。本综述总结了现有文献，重点关注早期NSCLC辅助治疗中靶向治疗和免疫治疗的最新进展及正在进行的试验。
